Elsevier

Biological Psychiatry

Volume 27, Issue 7, 1 April 1990, Pages 741-746
Biological Psychiatry

Naltrexone attenuates self-injurious behavior in mentally retarded subjects

https://doi.org/10.1016/0006-3223(90)90589-TGet rights and content

Abstract

The effect of naltrexone on the frequency of self-injurious behavior (SIB) was investigated in 6 male subjects with profound mental retardation. Following a double-blind placebo-controlled crossover design, naltrexone was administered in a dose of 50 mg once daily for 3 consecutive weeks. In 2 of 5 subjects, a significant decrease of SIB frequency could be demonstrated, and in 1, a tendency to a reduction was found. No effect on duration of restrain time was found in 3 subjects. These data suggest that disturbances of the endogenous opioid systems may be involved in the pathophysiology of SIB of certain patients.

References (20)

There are more references available in the full text version of this article.

Cited by (65)

  • Hypothalamic opioid-Melanocortin appetitive balance and addictive craving

    2011, Medical Hypotheses
    Citation Excerpt :

    It is also highly effective in the management of chronic alcoholism especially where its administration is supervised by a significant other [117–121]. It has also been described as having useful activity in a variety of other addictions including cannabis, amphetamine, cocaine, self-mutilation, overeating-obesity and gambling [2,111,116,122–132]. Naltrexone has been described as mildly stimulating the HPA axis in humans [133], an effect opposite to that described for opiate agonists (see above).

  • Plasma adrenocorticotropin responses to opioid blockade with naloxone: Generating a dose-response curve in a single session

    2000, Biological Psychiatry
    Citation Excerpt :

    Investigations with opioid antagonists have shown that CNS opioids impose tonic inhibition on the hypothalamic–pituitary–gonadal as well as the hypothalamic–pituitary–adrenal axes (Genazzani et al 1995; Inder et al 1995). Such studies have also suggested a role for the CNS opioid system in a number of neuropsychiatric disorders, including alcoholism (Wand et al 1998, 1999); autism (Campbell and Harris 1996); Gilles de la Tourette syndrome (Gillman and Sandyk 1985); obsessive-compulsive disorder (Keuler et al 1996); self-mutilation (Kars et al 1990; Lienemann and Walker 1989); trichotillomania (Carrion 1995); anorexia nervosa (Kaye et al 1987); and mood (Cohen et al 1983a, 1983b; Martin del Campo et al 1992, 1994). Moreover, antagonist studies have suggested that CNS opioids may help modulate learning and memory (Cohen et al 1983; Introini-Collison et al 1995; Izquierdo 1982; McGaugh et al 1986; Olson et al 1995).

  • Developmental Considerations for the Use of Naltrexone in Children and Adolescents

    2021, Journal of Pediatric Pharmacology and Therapeutics
View all citing articles on Scopus
View full text